We believe that UCK2 could be a potential novelty target to reverse cisplatin resistance of iCCA and the combined targeting of PI3K/AKT/mTOR signaling pathway and UCK2 has a potential to involve into the clinical use for iCCA patients. This evidence concerns the gene AKT1 and infantile convulsions and choreoathetosis.